Feverfew (Tanacetum parthenium L.): A systematic review

Anil Pareek, Manish Suthar, Garvendra S Rathore, Vijay Bansal, Anil Pareek, Manish Suthar, Garvendra S Rathore, Vijay Bansal

Abstract

Feverfew (Tanacetum parthenium L.) (Asteraceae) is a medicinal plant traditionally used for the treatment of fevers, migraine headaches, rheumatoid arthritis, stomach aches, toothaches, insect bites, infertility, and problems with menstruation and labor during childbirth. The feverfew herb has a long history of use in traditional and folk medicine, especially among Greek and early European herbalists. Feverfew has also been used for psoriasis, allergies, asthma, tinnitus, dizziness, nausea, and vomiting. The plant contains a large number of natural products, but the active principles probably include one or more of the sesquiterpene lactones known to be present, including parthenolide. Other potentially active constituents include flavonoid glycosides and pinenes. It has multiple pharmacologic properties, such as anticancer, anti-inflammatory, cardiotonic, antispasmodic, an emmenagogue, and as an enema for worms. In this review, we have explored the various dimensions of the feverfew plant and compiled its vast pharmacologic applications to comprehend and synthesize the subject of its potential image of multipurpose medicinal agent. The plant is widely cultivated to large regions of the world and its importance as a medicinal plant is growing substantially with increasing and stronger reports in support of its multifarious therapeutic uses.

Keywords: Anti-inflammatory; Tanacetum parthenium; migraine; parthenolide.

Conflict of interest statement

Conflict of Interest: None declared

Figures

Figure 1
Figure 1
Feverfew (Tanacetum parthenium): whole plant (a), flower (b), and feathery leaves (c)
Figure 2
Figure 2
Sesquiterpene lactones of Tanacetum parthenium
Figure 3
Figure 3
Flavonoids of Tanacetum parthenium
Figure 4
Figure 4
Flavonoids of Tanacetum parthenium

References

    1. Duke JA. Boca Raton, FL: CRC Press; 1985. CRC Handbook of Medicinal Herbs.
    1. Jackson B, McDonald RL. Magic and Medicine of Plants. In: Dobelis IN, editor. Pleasantville, NY: Reader's Digest Assoc; 1986.
    1. Meyer JE. Hammond IN: Hammond Book Co; 1934. The Herbalist.
    1. Castleman M. Emmaus, PA: Rodale Press; 1991. The Healing Herbs.
    1. Chavez M, Chavez P. Feverfew. Hosp Pharm. 1999;34:436–61.
    1. Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L.extract in mice and rats. J Ethnopharmacol. 1999;68:251–9.
    1. Heptinstall S, Awang DW, Dawson BA, Kindack D, Knight DW. Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of Commercial and Authenticated Feverfew Products. J Pharm Pharmacol. 1992;44:391–5.
    1. Setty AR, Sigal AH. Herbal medications commonly used in the practice of rheumatology: Mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum. 2005;34:773–84.
    1. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004;1:2286.
    1. Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew.Involvement of sesquiterpene lactones and other components. Biochem Pharmacol. 1992;43:2313–20.
    1. Bohlmann F, Zdero C. Sesquiterpene Lactones and Other Constituents from Tanacetum parthenium. Phytochemistry. 1982;21:2543–9.
    1. Groenewegen WA, Knight DW, Heptinstall S. Compounds extracted from feverfew that have anti-secretory activity contain an alpha-methylene butyrolactone unit. J Pharm Pharmacol. 1986;38:709–12.
    1. Milbrodt M, Schroder F, Konig W. 3,4--Epoxy-8-deoxycumambrin B, A sesquiterpene lactone from Tanacetum parthenium. Phytochemistry. 1997;44:471–4.
    1. Begley M, Hewlett M, Knight D. Revised structures for guaianolide-methylenebutyro-lactones from feverfew. Phytochemistry. 1989;28:940–3.
    1. Williams CA, Harborne JB, Eagles J. Variations in lipophilic and polar flavonoids in the genus Tanacetum. Phytochemistry. 1999;52:1301–6.
    1. Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry. 1999;51:417–23.
    1. Williams CA, Hoult JR, Harborne JB, Greenham J, Eagles J. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry. 1995;38:267–70.
    1. Long C, Sauleau P, David B. Bioactive flavonoids of Tanacetum parthenium revisited. Phytochemistry. 2003;64:567–9.
    1. Hall I, Lee K, Starnes C, Sumida Y, Wu R, Waddell T. Anti-inflammatory activity sesquiterpene lactones and related compounds. J Pharm Sci. 1979;68:537–42.
    1. Akpulat H, Tepe B, Sokmen A, Daferera D, Polissiou M. Composition of the essential oils of Tanacetum argyrophyllum (C. Koch) Tvzel. var. argyrophyllum and Tanacetum parthenium (L.) Schultz Bip. (Asteraceae) from Turkey. Biochem Syst Ecol. 2005;33:511–6.
    1. Kisiel W, Stojakowska A. A sesquiterpene coumarin ether from transformed roots of Tanacetum parthenium. Phytochemistry. 1997;46:515–6.
    1. Laiking S, Brown G. Coniferaldehyde derivatives from tissue culture of Artemisia annua and Tanacetum parthenium. Phytochemistry. 1999;50:781–5.
    1. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001;8:759–66.
    1. Collier HO, Butt NM, McDonald WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet. 1980;2:922–3.
    1. Brown AM, Edwards CM, Davey MR, Power JB, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium [L.] Schultz-Bip.): Assessment by inhibition of human polymorphonuclear leukocyte chemiluminescence in vitro. J Pharm Pharmacol. 1997;49:558–61.
    1. Loecshe EW, Mazurov AV, Voyno-Yasenetskaya TA, Groenewegnen WA, Heptinstall S, Repin VS. Feverfew-an antithrombotic drug.? Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115:181–4.
    1. Makheja AN, Bailey JM. The active principle in feverfew. Lancet. 1981;2:1054–7.
    1. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet. 1985;1:1071–4.
    1. Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium) Prostaglandins Leukot Med. 1982;8:653–60.
    1. Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol. 1988;40:743–5.
    1. Neill LA, Barrett ML, Lewis GP. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: A cytotoxic effect. Br J Clin Pharmacol. 1987;23:81–3.
    1. Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. J Pharm Pharmacol. 1992;44:737–40.
    1. Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew and vascular smooth muscle: Extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med. 1993;59:20–5.
    1. Barsby RW, Knight DW, McFadzean I. A chloroform extract of the herb feverfew blocks voltage-dependent potassium currents recorded from single smooth muscle cells. J Pharm Pharmacol. 1993;45:641–5.
    1. Bejar E. Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. J Ethnopharmacol. 1996;50:1–12.
    1. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behavior via neutralization of sulphydryl groups. J Pharm Pharmacol. 1987;39:459–65.
    1. Yasenetskaya TA, Loesche W, Groenewegen WA, Heptinstall S, Repin VS, Till U. Effects of an extract of feverfew on endothelial cell integrity and on cAMP in rabbit perfused aorta. J Pharm Pharmacol. 1988;40:501–2.
    1. Heptinstall S, Groenewegen S, Spangenberg P, Losche W. Inhibition of platelet behaviour by feverfew: A mechanism of action involving sulphydryl groups. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115:447–9.
    1. Krause S, Arese P, Heptinstall S, Losche W. Influence of substances affecting cell sulfhydryl/disulfide status on adherence of human monocytes. Arzneimittelforschung. 1990;40:689–92.
    1. Hayes NA, Foreman JC. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol. 1987;39:466–70.
    1. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, Dias Filho BP, Morgado-Díaz JA, de Souza W, et al. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother. 2005;49:176–82.
    1. Zhang S, Ong CN, Shen SM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett. 2004;208:143–53.
    1. Zhang S, Ong CN, Shen HM. Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett. 2004;211:175–88.
    1. Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med. 1999;65:126–9.
    1. Miglietta A, Bozzo F, Gabriel L, Bocca C. Microtubule-interfering activity of parthenolide. Chem Biol Interact. 2004;149:165–73.
    1. Kapadia GJ, Azuine MA, Tokuda H, Hang E, Mukainaka T, Nishino H, et al. Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation. Pharmacol Res. 2002;45:213–20.
    1. Feverfew-a new drug or an old wives′ remedy? Lancet. 1985;1:1084.
    1. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985;291:569–73.
    1. Waller PC, Ramsay LE. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985;291:1128.
    1. Murphy JJ, Heptinstall S, Mitchell JL. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–92.
    1. Groenewegen WA, Knight DW, Heptinstall S. Progress in the medicinal chemistry of the 0 herb feverfew. Prog Med Chem. 1992;29:217–38.
    1. Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet. 1982;2:776.
    1. Pfaffenrath V, Diener HC, Fischer M, Friede M, Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22:523–32.
    1. Awang DV. Fever few: A headache for the consumer. HerbalGram. 1993;29:34–5.
    1. Losche W, Mazurov AV, Heptinstall S, Groenewegen WA, Repin VS, Till U. An extract of feverfew inhibits interactions of human platelets with collagen substrates. Thromb Res. 1987;48:511–8.
    1. DeWeerdt C, Bootsma H, Hendriks H. Herbal medicines in migraine prevention.Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3:225–30.
    1. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: A double blind, placebo controlled study. Ann Rheum Dis. 1989;48:547–9.
    1. Smith TH, Liu X. Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts. Cell Immunol. 2001;209:89–96.
    1. Palevitch D. Feverfew (Tanacetum parthenium) as prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother Res. 1997;11:508–11.
    1. Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200–11.
    1. Vickers HR. Feverfew and migraine. Br Med J. 1985;291:827.
    1. Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: A comparison of chronic feverfew users and matched non-users. Hum Toxicol. 1988;7:145–52.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit